tiprankstipranks
CompuGroup Medical SE (DE:COP)
HAMBURG:COP

CompuGroup Medical (COP) AI Stock Analysis

34 Followers

Top Page

DE:COP

CompuGroup Medical

(Hamburg:COP)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 5.2)
Rating:60Neutral
Price Target:
€28.00
▲(18.54% Upside)
Action:ReiteratedDate:10/22/25
CompuGroup Medical's overall stock score is driven by stable financial performance and operational efficiency. However, high valuation metrics and technical indicators suggest caution. The lack of earnings call data and corporate events limits additional insights.
Positive Factors
Recurring SaaS and diversified revenue streams
A mixed model of one‑time license sales plus subscription and cloud SaaS creates recurring revenue and higher customer lifetime value. This durability improves predictability, supports retention and upsell, and underpins multi‑year cash flow visibility for reinvestment and debt servicing.
Negative Factors
Moderate leverage and reliance on debt financing
A moderate debt load reduces financial flexibility and raises sensitivity to interest costs and refinancing cycles. Over a multi‑month horizon this can constrain strategic moves, limit opportunistic M&A, and force prioritization of cash to debt service rather than growth or shareholder distributions.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring SaaS and diversified revenue streams
A mixed model of one‑time license sales plus subscription and cloud SaaS creates recurring revenue and higher customer lifetime value. This durability improves predictability, supports retention and upsell, and underpins multi‑year cash flow visibility for reinvestment and debt servicing.
Read all positive factors

CompuGroup Medical (COP) vs. iShares MSCI Germany ETF (EWG)

CompuGroup Medical Business Overview & Revenue Model

Company Description
CompuGroup Medical (COP) is a leading global eHealth company that provides software solutions for healthcare providers, including hospitals, practices, and pharmacies. The company operates primarily in the healthcare IT sector, offering a wide ran...
How the Company Makes Money
CompuGroup Medical generates revenue through multiple streams, primarily by selling software licenses and providing subscription-based services to healthcare providers. Their core revenue model includes one-time fees for software licenses, ongoing...

CompuGroup Medical Financial Statement Overview

Summary
CompuGroup Medical demonstrates steady revenue growth and operational efficiency, with solid EBIT and EBITDA margins. However, challenges in net profitability and leverage management remain.
Income Statement
70
Positive
Balance Sheet
65
Positive
Cash Flow
75
Positive
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.16B1.15B1.19B1.13B1.03B837.26M
Gross Profit821.16M965.14M1.01B958.16M285.89M712.95M
EBITDA197.37M206.90M215.84M231.36M216.63M192.49M
Net Income27.00M34.60M45.92M73.41M68.97M73.19M
Balance Sheet
Total Assets2.02B1.97B1.90B1.94B1.79B1.57B
Cash, Cash Equivalents and Short-Term Investments128.64M107.61M64.54M90.96M107.63M75.61M
Total Debt826.65M879.99M766.94M786.47M741.31M554.54M
Total Liabilities1.37B1.32B1.23B1.27B1.18B926.84M
Stockholders Equity651.09M647.91M667.68M672.42M612.07M638.67M
Cash Flow
Free Cash Flow84.57M65.66M104.11M63.99M87.78M94.20M
Operating Cash Flow143.96M128.88M179.53M145.03M165.27M149.93M
Investing Cash Flow-108.83M-105.28M-124.33M-145.41M-163.98M-457.12M
Financing Cash Flow-35.70M18.81M-80.69M-16.36M30.15M338.07M

CompuGroup Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price23.62
Price Trends
50DMA
27.00
Positive
100DMA
25.92
Positive
200DMA
24.88
Positive
Market Momentum
MACD
0.05
Negative
RSI
57.50
Neutral
STOCH
64.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:COP, the sentiment is Positive. The current price of 23.62 is below the 20-day moving average (MA) of 27.02, below the 50-day MA of 27.00, and below the 200-day MA of 24.88, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 57.50 is Neutral, neither overbought nor oversold. The STOCH value of 64.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:COP.

CompuGroup Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
€41.13M14.2618.76%3.86%-5.72%-25.19%
65
Neutral
€2.23B17.816.77%1.50%7.82%-19.80%
65
Neutral
€55.30M6.0914.89%6.36%8.24%140.53%
60
Neutral
€1.45B50.284.19%0.20%1.16%-43.53%
58
Neutral
€3.71B24.0111.14%1.62%-0.50%-13.97%
54
Neutral
€362.32M13.087.22%0.85%12.37%196.11%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:COP
CompuGroup Medical
27.45
5.44
24.70%
DE:ADN1
adesso AG
55.50
-35.22
-38.83%
DE:BC8
Bechtle Aktiengesellschaft
29.46
-3.48
-10.58%
DE:AFX
Carl Zeiss Meditec
24.88
-26.90
-51.96%
DE:M3V
MeVis Medical Solutions
22.60
-2.07
-8.39%
DE:AJ91
DocCheck AG
10.90
2.18
25.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 22, 2025